Impact of Nanoliposomes on Hepatitis Virus Pathways: A narrative Review Nanoliposomes & Hepatitis Virus Pathways
Article Sidebar
Main Article Content
Abstract
Hepatitis viruses keep up to remain a significant worldwide health threat owing to their chronic nature, severe hepatic consequences, accompanied with the limited effectiveness of standard treatments. Nanoliposomes, which are lipid-based nanocarriers, have a lot of potential for improving the administration of antiviral drugs by making them more bioavailable, targeting the liver, and changing how the immune system works. This study intends to focus on the latest developments in the design, physicochemical properties, and processes of nanoliposomes that stop the hepatitis virus from spreading, with an emphasis on the hepatitis B and C viruses. Recent investigations demonstrate their capacity to improve antiviral drug stability, promote hepatic macrophage targeting, and impede viral multiplication, while diminishing systemic toxicity. Additionally, the research article addresses biocompatibility issues, the constraints of existing methodologies, and future prospects for the incorporation of nanoliposomes into combination therapies that include nucleoside analogues, immune-stimulants, and vaccines. Nanoliposome- based systems are a promising and potentially transformative approach for enhancing the therapeutic management of viral hepatitis.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. Hamdi M, Mohamed Abdel-Bar H, Elmowafy E, T. Al-Jamal K et al. An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect. 2020. ncbi.nlm.nih.gov
2. Singh L, Indermun S, Govender M, Kumar P et al. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. 2018. ncbi.nlm.nih.gov
3. Tripathi SK, Li Y, Luo G. Syndecan 2 proteoglycan serves as a hepatitis B virus cell attachment receptor. Journal of Virology. 2025. asm.org
4. Shi Y, Du L, Lv D, Li Y et al. Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases. 2021. ncbi.nlm.nih.gov
5. AbouSamra MM. Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications. Journal of Liposome Research. 2024. [HTML]
6. Void-Holmes J, Cartee D. Blood-Borne and Related Pathogens. Infection Control in the Dental Office in the Era of COVID-19. 2024 Oct 14:27. [HTML]
7- Koichi Watashi, Stephan Urban, Wenjun Li, Takaji Wakita .NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry. Int. J. Mol. Sci. 2014, 15(2), 2892-2905
8. Aslam H, Oza F, Ahmed K, Kopel J, Aloysius MM, Ali A, Dahiya DS, Aziz M, Perisetti A, Goyal H. The role of red cell distribution width as a prognostic marker in chronic liver disease: a literature review. International Journal of Molecular Sciences. 2023 Feb 9;24(4):3487. mdpi.com
9- Shiv Kumar Sarin1 • Ashok Choudhury1 • Manoj K. Sharma1 • Rakhi Maiwall1 • Mamun Al Mahtab2 • Salimur Rahman2 • Sanjiv Saigal3 • Neeraj Saraf3 • A. S. Soin3 etal . Acute‑on‑chronic liver failure: consensus recommendations of the Asian Pacifc association for the study of the liver (APASL): an update. Hepatology International (2019) 13:353–390
10-Ul Islam K, Anwar S, A. Patel A, Tarek Mirdad M et al. Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response. 2023. ncbi.nlm.nih.gov
11. Wang Y, Gao L. Cholesterol: A friend to viruses. International reviews of immunology. 2024. researchgate.net
12. Pei J, Tian Y, Ye W, Han J, Dang Y, Cheng T, Wang W, Zhao Y, Ye W, Huangfu S, Li Y. A novel recombinant ORF7-siRNA delivered by flexible nano-liposomes inhibits varicella zoster virus infection. Cell & Bioscience. 2023 Sep 12;13(1):167. springer.com
13- Saman Yasamineh1,2, Hesam Ghafouri Kalajahi3, Pooneh Yasamineh1, Yalda Yazdani4, Omid Gholizadeh5, Raheleh Tabatabaie6 etal. An overview on nanoparticle-based strategies to fght viral infections with a focus on COVID-19. Journal of Nanobiotechnology (2022) 20:440.
14. Miao J, Gao P, Li Q, He K et al. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. 2021. ncbi.nlm.nih.gov
15. . Maheshwari R, Kapoor D, Polaka S, Bhattacharya S, Prajapati B. Roadmap for Commercial Nanomedicine Development: Integrating Quality by Design Principles with Pharmaceutical Nanotechnology. Molecular Pharmaceutics. 2025 Jul 16. [HTML]
16. Eskandari V, Mehmandoust S, Farahani Z, Mohammad NP, Hadi A. Liposomes/nanoliposomes and surfaced-enhanced Raman scattering (SERS): a review. Vibrational Spectroscopy. 2023 May 1;126:103536. [HTML]
17. Damodaran A, Zachariah SM, Nair SC. Novel therapeutic approaches for the management of hepatitis infections. Therapeutic Delivery. 2024. [HTML]
18. Chen C, Liu J, Zhang H, Zhang H, Liang Y, Ye Q, Shen W, Luo H, Guo L. A Bait-and-Hook Hydrogel for Net Tumor Cells to Enhance Chemotherapy and Mitigate Metastatic Dissemination. Pharmaceutics. 2024 Nov 25;16(12):1516. mdpi.com
19. Mingzhu Li, Lei Liu, Xiaoli Li, Jingran Li, Chao Zhao, Yun Zhao, Xiaopeng Zhang، Panpan He, collaborators ، Xiaoyu Wu، Siwen Jiang. Lipid Nanoparticles Outperform Electroporation in Delivering Therapeutic HPV DNA Vaccines. Vaccines 2022, 10(11),
20. Mohajan HK. Prevention of Hepatitis B Virus (HBV) is Essential to Avoid Chronic Liver Disease. Innovation in Science and Technology. 2025. paradigmpress.org
21. Stroffolini T, Stroffolini G. A historical overview on the role of hepatitis B and C viruses as aetiological factors for hepatocellular carcinoma. Cancers. 2023. mdpi.com
22. Nasser N, Tonnerre P, Mansouri A, Asselah T. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Current Opinion in Virology. 2023. [HTML]
23. Filipe S. Pereira-Dutra Livia Teixeira Maria Fernanda de Souza Costa |Patrícia T. Bozza. Fat, fight, and beyond: The multiple roles of lipid droplets in infections and inflammation. j leukoc Biol.; 1-18.29 May 2019.
24. Pei J, Tian Y, Dang Y, Ye W, Liu X, Zhao N, Han J, Yang Y, Zhou Z, Zhu X, Zhang H. Flexible nano-liposomes-encapsulated recombinant UL8-siRNA (r/si-UL8) based on bioengineering strategy inhibits herpes simplex virus-1 infection. Antiviral Research. 2024 Aug 1;228:105936. [HTML]
25. Orosco FL. From Nature's Pharmacy to Swine Health: Harnessing Natural Compounds against PRRSV Infection. Slovenian Veterinary Research/Slovenski Veterinarski Zbornik. 2024 Jan 1;61(1). [HTML]
26. Singh L. An architecturally-configured nanoparticulate system for targeted treatment of hepatitis B virus infection. 2015. [PDF]
27. Anna Sak-Fong Lak. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. HEPATOLOGY COMMUNICATIONS, VOL. 0, NO. 0, 2018
28. Cardoso RV, Pereira PR, Freitas CS, Paschoalin VMF. Trends in drug delivery systems for natural bioactive molecules to treat health disorders: the importance of nano-liposomes. Pharmaceutics. 2022. mdpi.com
29. Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. International Journal of Molecular Sciences. 2023 Apr 1;24(7):6615. mdpi.com
30. Li G, Dai Z, Guo J. Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection. International Journal of Nanomedicine. 2025. tandfonline.com
31. Chandra P, Ruhela M, Kumar P, Porwal M, Verma A, Sharma H, Sachan N. Nanotechnology-based approaches for targeted drug delivery to the small intestine: advancements and challenges. Current Pharmaceutical Design. 2025 Jul;31(24):1939-57. [HTML]
32. Wang Z, Du K, Jin N, Tang B, Zhang W. Macrophage in liver fibrosis: identities and mechanisms. International Immunopharmacology. 2023 Jul 1;120:110357. sciencedirect.com
33. Caddeo C, Miglionico R, Rinaldi R, Nigro I et al. PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells. 2023. ncbi.nlm.nih.gov
34. Ge D, An R, Xue L, Qiu M, Zhu Y, Wen G, Shi Y, Ren H, Li W, Wang J. Developing Cell-Membrane-Associated Liposomes for Liver Diseases. ACS nano. 2024 Oct 15;18(43):29421-38. [HTML]
35. Asandem DA, Segbefia SP, Kusi KA, Bonney JHK. Hepatitis B virus infection: a mini review. Viruses. 2024. mdpi.com
36. Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol. 2006;58(3):321–6. doi: 10.1211/jpp.58.3.0005.
37 . Singh S, Vardhan H, Kotla NG, Maddiboyina B, Sharma D, Webster TJ. The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic. Int J Nanomedicine. 2016;11:1475–82. doi: 10.2147/IJN.S100253.
38. Beck J., Reidenbach D., Salomon N., Sahin U., Türeci Ö., Vormehr M., Kranz L. mRNA therapeutics in cancer immunotherapy. Mol. Cancer. 2021;20:69. doi: 10.1186/s12943-021-01348-0.
39. Guevara M., Persano F., Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front. Chem. 2020;8:589959. doi: 10.3389/fchem.2020.589959.
40. Shobaki N., Sato Y., Suzuki Y., Okabe N., Harashima H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J. Control. Release. 2020;325:235–248. doi: 10.1016/j.jconrel.2020.07.001.
41. Qiao L., Luo G.G. Human apolipoprotein E promotes hepatitis B virus infection and production. PLOS Pathog. 2019;15 doi: 10.1371/journal.ppat.1007874.
42. Chung, H. J., Chen, X., Yu, Y., Lee, H. K., Song, C. H., Choe, H., et al. (2018). A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis. FEBS Open Biol. 8, 130–145. doi: 10.1002/2211-5463.12357.
43. Choi, Y.-M., Lee, S.-Y., and Kim, B.-J. (2019). Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma. Int. J. Mol. Sci. 20:597. doi: 10.3390/ijms20030597.
44. Dimri, M., and Satyanarayana, A. (2020). Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 12:491. doi: 10.3390/cancers12020491.
45. D'souza, S., Lau, K. C., Coffin, C. S., and Patel, T. R. (2020). Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J. Gastroenterol. 26:5759. doi: 10.3748/wjg.v26.i38.5759.
46. Iannacone, M., and Guidotti, L. G. (2022). Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 22, 19–32. doi: 10.1038/s41577-021-00549-4.
47. Kim, G. W., Imam, H., Khan, M., Mir, S. A., Kim, S. J., Yoon, S. K., et al. (2021). HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology 73, 533–547. doi: 10.1002/hep.31313.
48. Lin, C. L., Chu, Y. D., and Yeh, C. T. (2019). Emergence of oncogenic-enhancing hepatitis B virus X gene mutants in patients receiving suboptimal Entecavir treatment. Hepatology (Baltimore, Md). 69:2292. doi: 10.1002/hep.30423.
49. Dorst DN, Boss M, Rijpkema M, et al. (2021). Photodynamic therapy targeting macrophages using irdye700dx-liposomes decreases experimental arthritis development. Pharmaceutics 13:1868. doi: 10.3390/pharmaceutics13111868.
50. Khan AA, Allemailem KS, Almatroodi SA, et al. (2020). Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech 10:163. doi: 10.1007/s13205-020-2144-3.
51. Milani D, Athiyah U, Hariyadi DM, et al. (2019). Surface modifications of liposomes for drug targeting. In: Pathak YV, ed. Surface modification of nanoparticles for targeted drug delivery. Cham: Springer International Publishing, 207–20. doi: 10.1007/978-3-030-06115-9_11.
52. Pirmardvand Chegini S, Varshosaz J, Taymouri S. (2018). Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. Artif Cells Nanomed Biotechnol 46:502–14. doi: 10.1080/21691401.2018.1460373.
53. Ringhieri P, Mannucci S, Conti G, et al. (2017). Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Int J Nanomedicine 12:501–14. doi: 10.2147/IJN.S113607.
54. Santos MA, Goertz DE, Hynynen K. (2017). Focused ultrasound hyperthermia mediated drug delivery using thermosensitive liposomes and visualized with in vivo two-photon microscopy. Theranostics 7:2718–31. doi: 10.7150/thno.19662.
55. van Alem CMA, Metselaar JM, van Kooten C, et al. (2021). Recent advances in liposomal-based anti-inflammatory therapy. Pharmaceutics 13:1004. doi: 10.3390/pharmaceutics13071004.
56. Malik, S., Muhammad, K., Waheed, Y.: Nanotechnology: a revolution in modern industry. Molecules 28(2) (2023).
57. Shafique, M., Luo, X.: Nanotechnology in transportation vehicles: an overview of its applications, environmental, health and safety concerns. Materials (Basel) 12(15) (2019) .